Palbociclib + Ganitumab In Ewing Sarcoma
Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing Sarcoma
Sponsor: 1 Million 4 Anna Foundation
Terminated
The study closed early due to discontinuation of ganitumab supply.
Listed as NCT04129151, this PHASE2 trial focuses on Ewing Sarcoma and Ewing's Sarcoma Recurrent and remains terminated or withdrawn. Sponsored by 1 Million 4 Anna Foundation, it has been updated 14 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Dec 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jan 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- 1 Million 4 Anna Foundation
- Alan B. Slifka Foundation
- Carson Sarcoma Foundation
- ChemoWarrior: the eli sidler foundation
- Dana-Farber Cancer Institute
- Rutledge Cancer Foundation
- Teaming up to Fight Childhood Cancer
- i-ROK Foundation
For direct contact, visit the study record on ClinicalTrials.gov .